Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

Abstract Mosunetuzumab (Mosun) is a CD20xCD3 T‐cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step‐up dose regimen of 1/2/60/30 mg IV is designed to mitigate cytokine release syndrome (CRS) and maximize efficacy in early cycles. A population pha...

Descrición completa

Detalles Bibliográficos

Principais autores:	Brendan Bender, Chi‐Chung Li, Mathilde Marchand, David C. Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2024-06-01
Series:	Clinical and Translational Science
Acceso en liña:	https://doi.org/10.1111/cts.13825
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!